Accéder au contenu
Merck
  • The metabolic drug-drug interaction profile of Dabrafenib: in vitro investigations and quantitative extrapolation of the P450-mediated DDI risk.

The metabolic drug-drug interaction profile of Dabrafenib: in vitro investigations and quantitative extrapolation of the P450-mediated DDI risk.

Drug metabolism and disposition: the biological fate of chemicals (2014-04-22)
Sarah K Lawrence, Dung Nguyen, Chet Bowen, Lauren Richards-Peterson, Konstantine W Skordos
RÉSUMÉ

Dabrafenib is a potent ATP-competitive inhibitor for the V600 mutant b-rapidly accelerated fibrosarcoma (b-raf) kinase currently approved in the United States for the treatment of metastatic melanoma. Studies were conducted in human liver microsomes, recombinant human cytochrome P450 (P450) enzymes, and human hepatocytes to investigate the potential of dabrafenib and its major circulating metabolites to perpetrate pharmacokinetic drug-drug interactions (DDIs) as well as have their own pharmacokinetics affected (victim) by coadministered drugs. Dabrafenib metabolism was mediated by CYP2C8 (56% to 67%) and CYP3A4 (24%); in addition, it has demonstrated inhibition of CYP2C8, 2C9, 2C19, 3A4 (atorvastatin), and (nifedipine), with calculated IC50 values of 8.2, 7.2, 22.4, 16, and 32 μM. It also demonstrated metabolism-dependent inhibition of CYP3A4 with a maximal inactivation rate constant of 0.040 minute(-1) and a concentration required to achieve half-maximal inactivation for CYP3A4 of 38 μM. Hydroxy-dabrafenib inhibited CYP1A2, 2C9, and 3A4 (midazolam) with calculated IC50 values of 83, 29, and 44 μM, and carboxy-dabrafenib did not inhibit any of the P450 enzymes tested. Desmethyl-dabrafenib inhibited CYP2B6, 2C8, 2C9, 2C19, and 3A4 (midazolam, atorvastatin, and nifedipine) with calculated IC50 values of 78, 47, 6.3, 36, 17, 20, and 28 μM, respectively. At 30 μM dabrafenib showed increases in CYP2B6 and CYP3A4 mRNA expression indicative of induction. The potential clinical relevance of these findings was explored by using mechanistic static mathematical models to estimate the magnitude of change (area under the curve change) as a result of P450-mediated DDI interactions. This risk-assessment approach indicated that dabrafenib is unlikely to perpetrate any in vivo DDIs by inhibition mechanisms, but is a likely inducer of CYP3A4 and a victim of CYP3A4 and CYP2C8 inhibitors. Furthermore, inclusion of the in vitro drug interaction data for dabrafenib metabolites did not impact the overall clinical risk assessment.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Dexaméthasone, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Rifampicine, ≥95% (HPLC), powder or crystals
Sigma-Aldrich
Dexaméthasone, ≥98% (HPLC), powder
Sigma-Aldrich
Rifampicine, suitable for plant cell culture, BioReagent, ≥95% (HPLC), powder or crystals
Sigma-Aldrich
Dexaméthasone, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Sigma-Aldrich
Omeprazole, solid
Sigma-Aldrich
Quinidine, anhydrous
USP
Dexaméthasone, United States Pharmacopeia (USP) Reference Standard
USP
Omeprazole, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Furafylline, ≥98% (HPLC)
Supelco
Omeprazole, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
5,5-Diphenylhydantoin, ≥98%
Sigma-Aldrich
Quinidine, crystallized, ≥98.0% (dried material, NT)
Supelco
Dexaméthasone, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Phenytoin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Dexaméthasone, meets USP testing specifications
Supelco
Phenytoin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Dexaméthasone, tested according to Ph. Eur.
Phenytoin, European Pharmacopoeia (EP) Reference Standard
Supelco
Omeprazole, analytical standard
Rifampicine, European Pharmacopoeia (EP) Reference Standard
Dexaméthasone, European Pharmacopoeia (EP) Reference Standard
Omeprazole for peak identification, European Pharmacopoeia (EP) Reference Standard
Supelco
Dexaméthasone, VETRANAL®, analytical standard
Dexaméthasone, European Pharmacopoeia (EP) Reference Standard
Omeprazole, European Pharmacopoeia (EP) Reference Standard
Dexaméthasone, European Pharmacopoeia (EP) Reference Standard
Dexaméthasone, British Pharmacopoeia (BP) Assay Standard
Phenytoin for system suitability, European Pharmacopoeia (EP) Reference Standard